- Home
- Products
- Customized ADCs
- SLC34A2
- Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC
Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC (CAT#: ADC-W-2573)
This ADC product is comprised of an anti-SLC34A2 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- SLC34A2
- Alternative Names
- SLC34A2; solute carrier family 34 (type II sodium/phosphate contransporter), member 2; NPTIIb; NAPI-3B; NAPI-IIb; sodium-dependent phosphate transport protein 2B; sodium/phosphate cotransporter 2B; type II sodium-dependent phosphate transporter 3b; solute carrier family 34 (sodium phosphate), member 2;
- Target Entrez Gene ID
- 10568
- Target UniProt ID
- O95436
- Overview
- The protein encoded by this gene is a pH-sensitive sodium-dependent phosphate transporter. Phosphate uptake is increased at lower pH. Defects in this gene are a cause of pulmonary alveolar microlithiasis. Three transcript variants encoding two different isoforms have been found for this gene.
- Overview
- Human Anti-SLC34A2 IgG1-kappa antibody, Lifastuzumab
- Generic name
- Lifastuzumab
- Host animal
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-ERBB2 (Trastuzumab)-AO-Mc-MMAE (Glyco MMAE) ADC (CAT#: ADC-W-392)
- Anti-S. aureus ClfA (Tefibazumab)-SPDB-DM4 ADC (CAT#: ADC-W-2133)
- Anti-IL1B (Gevokizumab)-SPDB-DM4 ADC (CAT#: ADC-W-1329)
- Anti-CD27 (Varlilumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2227)
- Anti-CD3E (Visilizumab)-SMCC-DM1 ADC (CAT#: ADC-W-842)
- Anti-IFNAR (Anifrolumab)-SMCC-DM1 ADC (CAT#: ADC-W-2054)
- Anti-ER-a36-SPDB-DM4 ADC (CAT#: ADC-W-206)
- Anti-MS4A1-VC-MMAE ADC-4 (CAT#: ADC-W-328)
- Anti-CFD (Lampalizumab)-MC-MMAF ADC (CAT#: ADC-W-982)
- Anti-HIV-1 (Suvizumab)-SMCC-DM1 ADC (CAT#: ADC-W-2108)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2573. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2575 | Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2571 | Anti-SLC34A2 (Lifastuzumab )-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2576 | Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-499 | Anti-SLC34A2 (Lifastuzumab)-VC-MMAE ADC | mc-VC-PABC | MMAE (Monomethyl auristatin E) |
| ADC-W-2572 | Anti-SLC34A2 (Lifastuzumab )-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-478 | Anti-ENPP3-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-493 | Anti-CD19-Mc-MMAF ADC-3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-452 | Anti-CD70-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2550 | Anti-CD74-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.